Previous 10 | Next 10 |
Cyteir Therapeutics, Inc. (CYT) Q4 2021 Results Conference Call March 16, 2022 04:30 PM ET Company Participants Lisa Hayes - VP, IR and Corporate Communications Dr. Markus Renschler - President and CEO Dave Gaiero - VP, Finance Andrew Gengos - Chief Business Officer Paul Secrist - Chief Scien...
Cyteir Therapeutics press release (NASDAQ:CYT): Q4 GAAP EPS of -$0.34 beats by $0.06. Q4 Cash and cash equivalents $189.72M For further details see: Cyteir Therapeutics GAAP EPS of -$0.34 beats by $0.06
- Continue to enroll in monotherapy and combination studies with CYT-0851 with potential for interim safety and efficacy data in second half 2022 - Progress achieved in key clinical milestones described in the 2021 IPO: Advanced CYT-0851 monotherapy to Phase 2 and initiated Phase 1 ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, will host a conference call and live audio webcast on Wednesday, March 16, 2022 at 4:30 p.m. ET to discuss f...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of Stephen Sands to its Board of Directors, to serve as a Class I director, ...
Cyteir Therapeutics (NASDAQ:CYT) said the first patient was dosed in a phase 2 expansion cohort of a phase 1/2 trial of CYT-0851 being evaluated for treating hematologic malignancies and solid tumors. "This signal-seeking study in six different cancers will give us the data that may...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 2 expansion cohort study of CYT-0851 monoth...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced the appointment of John F. Thero to its board of directors. Mr. Thero will chair the audit c...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that the first patient has been dosed in a Phase 1 trial evaluating CYT-0851 in combination ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD, will present at the 40th Annu...
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
NASDAQ Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...